SEC Company Response from REGENERX BIOPHARMACEUTICALS INC (RGRX) (CIK 0000707511) — Sep 3, 2021
REGENERX BIOPHARMACEUTICALS INC (RGRX) (CIK 0000707511)
Date: Sept. 3, 2021 · CIK: 0000707511 · Accession: 0001104659-21-112758
AI Filing Summary & Sentiment
File numbers found in text: 333-258873
Letter
Re:
September 3, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RegeneRx Biopharmaceuticals, Inc.
Registration Statement on Form S-1 (File No. 333-258873)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 5:00 PM on September 3, 2021 or as soon thereafter as is practicable.
RegeneRx Biopharmaceuticals, Inc.
/s/ J.J. Finkelstein
J.J. Finkelstein
Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
September 3, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
RegeneRx Biopharmaceuticals, Inc.
Registration Statement on Form S-1 (File No. 333-258873)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the undersigned respectfully requests that the effective date of the above-referenced Registration Statement
be accelerated so that the same will become effective at 5:00 PM on September 3, 2021 or as soon thereafter as is practicable.
RegeneRx Biopharmaceuticals, Inc.
/s/
J.J. Finkelstein
J.J. Finkelstein
Chief Executive Officer